25 XP   0   0   10

Pharmaron Beijing Co Ltd
Buy, Hold or Sell?

Let's analyse Pharmaron together

PenkeI guess you are interested in Pharmaron Beijing Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharmaron Beijing Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pharmaron Beijing Co Ltd

I send you an email if I find something interesting about Pharmaron Beijing Co Ltd.

Quick analysis of Pharmaron (30 sec.)










What can you expect buying and holding a share of Pharmaron? (30 sec.)

How much money do you get?

How much money do you get?
¥0.03
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥7.12
Expected worth in 1 year
¥7.15
How sure are you?
89.5%

+ What do you gain per year?

Total Gains per Share
¥0.26
Return On Investment
1.3%

For what price can you sell your share?

Current Price per Share
¥20.37
Expected price per share
¥18.50 - ¥24.90
How sure are you?
50%

1. Valuation of Pharmaron (5 min.)




Live pricePrice per Share (EOD)

¥20.37

Intrinsic Value Per Share

¥-5.65 - ¥-6.70

Total Value Per Share

¥1.47 - ¥0.42

2. Growth of Pharmaron (5 min.)




Is Pharmaron growing?

Current yearPrevious yearGrowGrow %
How rich?$1.7b$1.4b$196.4m12.0%

How much money is Pharmaron making?

Current yearPrevious yearGrowGrow %
Making money$53.7m$54.7m-$1m-1.9%
Net Profit Margin13.6%16.9%--

How much money comes from the company's main activities?

3. Financial Health of Pharmaron (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#40 / 1031

Most Revenue
#36 / 1031

Most Profit
#38 / 1031

Most Efficient
#108 / 1031

What can you expect buying and holding a share of Pharmaron? (5 min.)

Welcome investor! Pharmaron's management wants to use your money to grow the business. In return you get a share of Pharmaron.

What can you expect buying and holding a share of Pharmaron?

First you should know what it really means to hold a share of Pharmaron. And how you can make/lose money.

Speculation

The Price per Share of Pharmaron is ¥20.37. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharmaron.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharmaron, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥7.12. Based on the TTM, the Book Value Change Per Share is ¥0.01 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.06 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharmaron.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.030.1%0.030.2%0.040.2%0.030.1%0.030.1%
Usd Book Value Change Per Share0.030.2%0.000.0%0.010.1%0.050.3%0.050.3%
Usd Dividend Per Share0.030.1%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.060.3%0.010.0%0.020.1%0.060.3%0.060.3%
Usd Price Per Share4.30-6.45-14.14-12.63-12.63-
Price to Earnings Ratio39.36-47.33-104.77-126.78-126.78-
Price-to-Total Gains Ratio70.53--4.85-1,028.48-504.79-504.79-
Price to Book Ratio4.37-6.90-14.68-16.62-16.62-
Price-to-Total Gains Ratio70.53--4.85-1,028.48-504.79-504.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.819208
Number of shares354
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.000.05
Usd Total Gains Per Share0.010.06
Gains per Quarter (354 shares)3.1720.42
Gains per Year (354 shares)12.6881.68
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1111387372
22331616147154
33442925220236
44564233294318
55775541367400
66886849441482
779108158514564
890119466588646
91021210774661728
101131412082735810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%
Book Value Change Per Share2.02.00.050.0%9.03.00.075.0%16.03.00.084.2%16.03.00.084.2%16.03.00.084.2%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%
Total Gains per Share2.02.00.050.0%10.02.00.083.3%17.02.00.089.5%17.02.00.089.5%17.02.00.089.5%

Fundamentals of Pharmaron

About Pharmaron Beijing Co Ltd

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Preparation Process Development, and Production Services; Clinical Research Services; Macromolecule and Cell, and Gene Therapy Services; and Others. The company offers laboratory chemical services, including medicinal chemistry, synthetic chemistry, analytical and purification chemistry, and computer-aided drug design; bioscience services, such as in vitro and in vivo drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology, drug safety evaluation, and US laboratory services; and process development and production, material science/preparation, preparation development and production, and analytical development services. It also provides radiolabeling science and early clinical trial services; clinical trial and clinical research site management services; and macromolecular drug discovery and development, and production services (CDMO), as well as cell and gene therapy laboratory, and gene therapy CDMO services. In addition, the company provides safety assessment, and chemistry, manufacturing, and controls services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-03-11 04:18:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Pharmaron Beijing Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharmaron earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • A Net Profit Margin of 12.1% means that ¥0.12 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 12.1%. The company is making a huge profit. +2
  • The TTM is 13.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ12.1%TTM13.6%-1.5%
TTM13.6%YOY16.9%-3.3%
TTM13.6%5Y17.0%-3.5%
5Y17.0%10Y17.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.1%-159.2%+171.3%
TTM13.6%-202.3%+215.9%
YOY16.9%-263.0%+279.9%
5Y17.0%-452.4%+469.4%
10Y17.0%-589.0%+606.0%
1.1.2. Return on Assets

Shows how efficient Pharmaron is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • 1.6% Return on Assets means that Pharmaron generated ¥0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 1.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.8%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.6%TTM1.8%-0.2%
TTM1.8%YOY2.1%-0.3%
TTM1.8%5Y2.2%-0.4%
5Y2.2%10Y2.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6%-12.5%+14.1%
TTM1.8%-12.2%+14.0%
YOY2.1%-11.2%+13.3%
5Y2.2%-13.3%+15.5%
10Y2.2%-14.6%+16.8%
1.1.3. Return on Equity

Shows how efficient Pharmaron is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • 3.0% Return on Equity means Pharmaron generated ¥0.03 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 3.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.0%TTM3.5%-0.5%
TTM3.5%YOY3.9%-0.4%
TTM3.5%5Y3.6%-0.1%
5Y3.6%10Y3.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0%-16.0%+19.0%
TTM3.5%-15.8%+19.3%
YOY3.9%-13.9%+17.8%
5Y3.6%-18.2%+21.8%
10Y3.6%-19.1%+22.7%

1.2. Operating Efficiency of Pharmaron Beijing Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharmaron is operating .

  • Measures how much profit Pharmaron makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.0%-4.0%
TTM4.0%YOY17.0%-13.0%
TTM4.0%5Y15.6%-11.6%
5Y15.6%10Y15.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM4.0%-208.5%+212.5%
YOY17.0%-280.2%+297.2%
5Y15.6%-459.9%+475.5%
10Y15.6%-596.9%+612.5%
1.2.2. Operating Ratio

Measures how efficient Pharmaron is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.49 means that the operating costs are ¥1.49 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 1.491. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.478. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.491TTM1.478+0.013
TTM1.478YOY1.465+0.013
TTM1.4785Y1.453+0.025
5Y1.45310Y1.4530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4912.817-1.326
TTM1.4783.181-1.703
YOY1.4653.609-2.144
5Y1.4535.554-4.101
10Y1.4537.396-5.943

1.3. Liquidity of Pharmaron Beijing Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharmaron is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.94 means the company has ¥1.94 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 1.945. The company is able to pay all its short-term debts. +1
  • The TTM is 1.780. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.945TTM1.780+0.165
TTM1.780YOY2.316-0.536
TTM1.7805Y2.632-0.852
5Y2.63210Y2.6320.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9453.987-2.042
TTM1.7804.440-2.660
YOY2.3165.569-3.253
5Y2.6326.158-3.526
10Y2.6326.492-3.860
1.3.2. Quick Ratio

Measures if Pharmaron is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • A Quick Ratio of 0.85 means the company can pay off ¥0.85 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 0.847. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.744. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.847TTM0.744+0.104
TTM0.744YOY0.902-0.159
TTM0.7445Y0.930-0.187
5Y0.93010Y0.9300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8473.653-2.806
TTM0.7444.158-3.414
YOY0.9025.515-4.613
5Y0.9306.012-5.082
10Y0.9306.206-5.276

1.4. Solvency of Pharmaron Beijing Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharmaron assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharmaron to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.43 means that Pharmaron assets are financed with 43.4% credit (debt) and the remaining percentage (100% - 43.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 0.434. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.455. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.434TTM0.455-0.021
TTM0.455YOY0.452+0.003
TTM0.4555Y0.374+0.081
5Y0.37410Y0.3740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4340.336+0.098
TTM0.4550.330+0.125
YOY0.4520.267+0.185
5Y0.3740.367+0.007
10Y0.3740.378-0.004
1.4.2. Debt to Equity Ratio

Measures if Pharmaron is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • A Debt to Equity ratio of 81.9% means that company has ¥0.82 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 0.819. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.875. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.819TTM0.875-0.056
TTM0.875YOY0.837+0.037
TTM0.8755Y0.662+0.213
5Y0.66210Y0.6620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8190.376+0.443
TTM0.8750.398+0.477
YOY0.8370.334+0.503
5Y0.6620.431+0.231
10Y0.6620.476+0.186

2. Market Valuation of Pharmaron Beijing Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Pharmaron generates.

  • Above 15 is considered overpriced but always compare Pharmaron to the Biotechnology industry mean.
  • A PE ratio of 39.36 means the investor is paying ¥39.36 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharmaron Beijing Co Ltd:

  • The EOD is 25.782. Based on the earnings, the company is overpriced. -1
  • The MRQ is 39.362. Based on the earnings, the company is overpriced. -1
  • The TTM is 47.333. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD25.782MRQ39.362-13.581
MRQ39.362TTM47.333-7.971
TTM47.333YOY104.772-57.439
TTM47.3335Y126.776-79.443
5Y126.77610Y126.7760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD25.782-2.697+28.479
MRQ39.362-2.422+41.784
TTM47.333-2.709+50.042
YOY104.772-4.116+108.888
5Y126.776-6.257+133.033
10Y126.776-6.478+133.254
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharmaron Beijing Co Ltd:

  • The EOD is 961.268. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 1,467.621. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2,097.595. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD961.268MRQ1,467.621-506.353
MRQ1,467.621TTM-2,097.595+3,565.217
TTM-2,097.595YOY32.926-2,130.521
TTM-2,097.5955Y-611.671-1,485.924
5Y-611.67110Y-611.6710.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD961.268-3.344+964.612
MRQ1,467.621-2.939+1,470.560
TTM-2,097.595-3.486-2,094.109
YOY32.926-5.592+38.518
5Y-611.671-8.464-603.207
10Y-611.671-8.872-602.799
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharmaron is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.37 means the investor is paying ¥4.37 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharmaron Beijing Co Ltd:

  • The EOD is 2.860. Based on the equity, the company is underpriced. +1
  • The MRQ is 4.366. Based on the equity, the company is fair priced.
  • The TTM is 6.896. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.860MRQ4.366-1.507
MRQ4.366TTM6.896-2.530
TTM6.896YOY14.677-7.780
TTM6.8965Y16.619-9.722
5Y16.61910Y16.6190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8602.198+0.662
MRQ4.3662.042+2.324
TTM6.8962.121+4.775
YOY14.6772.907+11.770
5Y16.6193.682+12.937
10Y16.6194.114+12.505
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Pharmaron Beijing Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2350.007+3238%0.107+119%0.375-37%0.375-37%
Book Value Per Share--7.1226.916+3%6.977+2%5.717+25%5.717+25%
Current Ratio--1.9451.780+9%2.316-16%2.632-26%2.632-26%
Debt To Asset Ratio--0.4340.455-5%0.452-4%0.374+16%0.374+16%
Debt To Equity Ratio--0.8190.875-6%0.837-2%0.662+24%0.662+24%
Dividend Per Share--0.2060.058+257%0.068+203%0.042+391%0.042+391%
Eps--0.1980.246-20%0.266-26%0.205-4%0.205-4%
Free Cash Flow Per Share--0.005-0.037+802%-0.119+2344%-0.019+463%-0.019+463%
Free Cash Flow To Equity Per Share--0.0050.251-98%-0.358+6862%0.144-96%0.144-96%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---6.702--------
Intrinsic Value_10Y_min---5.651--------
Intrinsic Value_1Y_max---0.305--------
Intrinsic Value_1Y_min---0.299--------
Intrinsic Value_3Y_max---1.195--------
Intrinsic Value_3Y_min---1.135--------
Intrinsic Value_5Y_max---2.423--------
Intrinsic Value_5Y_min---2.225--------
Market Cap30266967548.160-84%55570625444.10079555505357.899-30%151758047806.186-63%137756767729.798-60%137756767729.798-60%
Net Profit Margin--0.1210.136-11%0.169-29%0.170-29%0.170-29%
Operating Margin---0.040-100%0.170-100%0.156-100%0.156-100%
Operating Ratio--1.4911.478+1%1.465+2%1.453+3%1.453+3%
Pb Ratio2.860-53%4.3666.896-37%14.677-70%16.619-74%16.619-74%
Pe Ratio25.782-53%39.36247.333-17%104.772-62%126.776-69%126.776-69%
Price Per Share20.370-53%31.10046.587-33%102.135-70%91.248-66%91.248-66%
Price To Free Cash Flow Ratio961.268-53%1467.621-2097.595+243%32.926+4357%-611.671+142%-611.671+142%
Price To Total Gains Ratio46.197-53%70.532-4.854+107%1028.481-93%504.792-86%504.792-86%
Quick Ratio--0.8470.744+14%0.902-6%0.930-9%0.930-9%
Return On Assets--0.0160.018-13%0.021-25%0.022-28%0.022-28%
Return On Equity--0.0300.035-14%0.039-23%0.036-18%0.036-18%
Total Gains Per Share--0.4410.065+581%0.175+152%0.417+6%0.417+6%
Usd Book Value--1761373344.1371631323107.246+8%1434873966.594+23%1219591831.678+44%1219591831.678+44%
Usd Book Value Change Per Share--0.0330.001+3238%0.015+119%0.052-37%0.052-37%
Usd Book Value Per Share--0.9860.957+3%0.966+2%0.791+25%0.791+25%
Usd Dividend Per Share--0.0290.008+257%0.009+203%0.006+391%0.006+391%
Usd Eps--0.0270.034-20%0.037-26%0.028-4%0.028-4%
Usd Free Cash Flow--1310109.021-7407381.952+665%-24445264.299+1966%-3905826.394+398%-3905826.394+398%
Usd Free Cash Flow Per Share--0.001-0.005+802%-0.016+2344%-0.003+463%-0.003+463%
Usd Free Cash Flow To Equity Per Share--0.0010.035-98%-0.050+6862%0.020-96%0.020-96%
Usd Market Cap4188948308.665-84%7690974561.46311010481941.533-30%21003313816.376-63%19065536653.804-60%19065536653.804-60%
Usd Price Per Share2.819-53%4.3046.448-33%14.135-70%12.629-66%12.629-66%
Usd Profit--48847583.49553717714.705-9%54739723.730-11%42934919.161+14%42934919.161+14%
Usd Revenue--404147208.457395261787.778+2%330258066.334+22%256120648.307+58%256120648.307+58%
Usd Total Gains Per Share--0.0610.009+581%0.024+152%0.058+6%0.058+6%
 EOD+4 -4MRQTTM+21 -14YOY+20 -155Y+15 -2010Y+15 -20

3.2. Fundamental Score

Let's check the fundamental score of Pharmaron Beijing Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1525.782
Price to Book Ratio (EOD)Between0-12.860
Net Profit Margin (MRQ)Greater than00.121
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.847
Current Ratio (MRQ)Greater than11.945
Debt to Asset Ratio (MRQ)Less than10.434
Debt to Equity Ratio (MRQ)Less than10.819
Return on Equity (MRQ)Greater than0.150.030
Return on Assets (MRQ)Greater than0.050.016
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Pharmaron Beijing Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose20.350
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Interest Income  6,56158,51665,076-58,5496,52714,23820,765-56,453-35,688



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets22,476,013
Total Liabilities9,749,327
Total Stockholder Equity11,904,941
 As reported
Total Liabilities 9,749,327
Total Stockholder Equity+ 11,904,941
Total Assets = 22,476,013

Assets

Total Assets22,476,013
Total Current Assets7,220,417
Long-term Assets15,255,595
Total Current Assets
Cash And Cash Equivalents 2,058,719
Short-term Investments 924,252
Net Receivables 2,221,757
Inventory 995,034
Other Current Assets 503,715
Total Current Assets  (as reported)7,220,417
Total Current Assets  (calculated)6,703,477
+/- 516,940
Long-term Assets
Property Plant Equipment 9,680,337
Goodwill 2,763,654
Intangible Assets 786,044
Long-term Assets Other 262,375
Long-term Assets  (as reported)15,255,595
Long-term Assets  (calculated)13,492,410
+/- 1,763,185

Liabilities & Shareholders' Equity

Total Current Liabilities3,712,925
Long-term Liabilities6,036,402
Total Stockholder Equity11,904,941
Total Current Liabilities
Short Long Term Debt 534,848
Accounts payable 400,934
Other Current Liabilities 29,260
Total Current Liabilities  (as reported)3,712,925
Total Current Liabilities  (calculated)965,042
+/- 2,747,882
Long-term Liabilities
Long term Debt 4,761,816
Capital Lease Obligations Min Short Term Debt617,049
Long-term Liabilities Other 115,863
Long-term Liabilities  (as reported)6,036,402
Long-term Liabilities  (calculated)5,494,728
+/- 541,674
Total Stockholder Equity
Retained Earnings 4,934,072
Total Stockholder Equity (as reported)11,904,941
Total Stockholder Equity (calculated)4,934,072
+/- 6,970,868
Other
Capital Stock1,786,732
Common Stock Shares Outstanding 1,786,837
Net Debt 3,237,945
Net Invested Capital 17,201,605
Net Working Capital 3,507,493
Property Plant and Equipment Gross 9,680,337



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
5,143,597
5,347,327
5,574,184
9,935,038
9,276,892
9,983,834
10,486,354
11,908,793
12,761,893
17,037,700
17,536,056
18,389,124
18,660,921
18,966,871
19,706,905
20,492,557
21,047,569
22,390,082
22,476,013
22,476,01322,390,08221,047,56920,492,55719,706,90518,966,87118,660,92118,389,12417,536,05617,037,70012,761,89311,908,79310,486,3549,983,8349,276,8929,935,0385,574,1845,347,3275,143,597
   > Total Current Assets 
1,787,068
1,604,707
1,715,836
5,944,451
5,188,426
5,283,466
5,542,103
5,540,378
5,064,977
8,818,013
8,654,911
8,643,502
7,646,205
7,001,671
6,652,813
6,536,007
6,558,584
7,431,010
7,220,417
7,220,4177,431,0106,558,5846,536,0076,652,8137,001,6717,646,2058,643,5028,654,9118,818,0135,064,9775,540,3785,542,1035,283,4665,188,4265,944,4511,715,8361,604,7071,787,068
       Cash And Cash Equivalents 
825,982
339,543
318,190
4,459,852
3,558,420
3,053,203
2,954,144
2,942,353
2,210,849
5,968,797
4,289,872
3,543,820
2,913,716
2,848,680
2,042,502
1,497,484
2,055,504
2,512,732
2,058,719
2,058,7192,512,7322,055,5041,497,4842,042,5022,848,6802,913,7163,543,8204,289,8725,968,7972,210,8492,942,3532,954,1443,053,2033,558,4204,459,852318,190339,543825,982
       Short-term Investments 
0
125,000
142,000
183,451
375,851
727,472
1,046,159
910,010
1,049,825
757,147
1,661,953
1,554,621
1,431,492
597,634
698,213
745,362
491,098
637,198
924,252
924,252637,198491,098745,362698,213597,6341,431,4921,554,6211,661,953757,1471,049,825910,0101,046,159727,472375,851183,451142,000125,0000
       Net Receivables 
621,472
654,058
752,397
1,024,596
953,189
1,082,086
1,120,672
1,243,755
1,293,602
1,373,332
1,441,428
1,519,620
1,657,766
1,986,708
2,275,476
1,881,882
2,066,227
2,619,823
2,221,757
2,221,7572,619,8232,066,2271,881,8822,275,4761,986,7081,657,7661,519,6201,441,4281,373,3321,293,6021,243,7551,120,6721,082,086953,1891,024,596752,397654,058621,472
       Inventory 
153,249
143,106
161,330
157,397
189,093
129,627
257,317
281,617
318,800
445,341
567,550
680,040
788,649
923,707
1,017,870
1,041,461
1,072,500
1,039,349
995,034
995,0341,039,3491,072,5001,041,4611,017,870923,707788,649680,040567,550445,341318,800281,617257,317129,627189,093157,397161,330143,106153,249
       Other Current Assets 
98,909
224,207
133,772
119,154
111,874
298,354
163,810
162,643
191,902
273,396
694,108
265,689
854,581
264,120
618,753
919,447
329,943
396,867
503,715
503,715396,867329,943919,447618,753264,120854,581265,689694,108273,396191,902162,643163,810298,354111,874119,154133,772224,20798,909
   > Long-term Assets 
3,356,529
3,742,620
3,858,348
3,990,587
4,088,466
4,700,368
4,944,251
6,368,414
7,696,916
8,219,687
8,881,144
9,745,622
11,014,716
11,965,201
13,054,092
13,956,551
14,488,986
14,959,072
15,255,595
15,255,59514,959,07214,488,98613,956,55113,054,09211,965,20111,014,7169,745,6228,881,1448,219,6877,696,9166,368,4144,944,2514,700,3684,088,4663,990,5873,858,3483,742,6203,356,529
       Property Plant Equipment 
2,394,011
2,645,426
2,729,180
2,882,287
2,922,348
3,646,923
3,345,941
3,798,703
4,202,298
4,743,914
5,100,169
5,810,564
6,533,965
7,150,874
7,655,254
8,285,750
8,761,313
9,303,961
9,680,337
9,680,3379,303,9618,761,3138,285,7507,655,2547,150,8746,533,9655,810,5645,100,1694,743,9144,202,2983,798,7033,345,9413,646,9232,922,3482,882,2872,729,1802,645,4262,394,011
       Goodwill 
137,397
201,313
205,165
203,286
205,402
364,225
358,989
1,166,172
1,172,594
1,804,929
1,813,810
2,096,265
2,363,931
2,535,957
2,562,966
2,687,865
2,687,644
2,814,376
2,763,654
2,763,6542,814,3762,687,6442,687,8652,562,9662,535,9572,363,9312,096,2651,813,8101,804,9291,172,5941,166,172358,989364,225205,402203,286205,165201,313137,397
       Intangible Assets 
390,090
34,197
418,122
420,574
416,634
464,168
460,745
566,076
638,411
654,434
649,751
692,935
748,408
724,385
723,007
802,535
828,790
805,050
786,044
786,044805,050828,790802,535723,007724,385748,408692,935649,751654,434638,411566,076460,745464,168416,634420,574418,12234,197390,090
       Other Assets 
329,848
323,206
312,703
294,141
318,993
141,988
339,881
435,759
1,234,049
520,018
659,423
383,189
527,010
574,082
850,021
0
0
941,553
0
0941,55300850,021574,082527,010383,189659,423520,0181,234,049435,759339,881141,988318,993294,141312,703323,206329,848
> Total Liabilities 
2,310,379
2,431,071
2,503,299
2,097,020
1,356,007
1,774,897
1,956,455
2,975,053
3,609,823
7,534,435
7,632,127
8,093,818
8,316,165
8,677,751
9,165,742
9,652,690
9,772,959
10,083,179
9,749,327
9,749,32710,083,1799,772,9599,652,6909,165,7428,677,7518,316,1658,093,8187,632,1277,534,4353,609,8232,975,0531,956,4551,774,8971,356,0072,097,0202,503,2992,431,0712,310,379
   > Total Current Liabilities 
1,281,146
1,436,764
1,457,742
1,269,681
998,747
1,325,161
1,326,170
1,981,789
2,298,653
2,515,522
2,551,891
2,981,997
3,086,492
3,395,331
3,646,401
3,912,433
3,934,762
4,042,671
3,712,925
3,712,9254,042,6713,934,7623,912,4333,646,4013,395,3313,086,4922,981,9972,551,8912,515,5222,298,6531,981,7891,326,1701,325,161998,7471,269,6811,457,7421,436,7641,281,146
       Short-term Debt 
497,392
409,289
415,449
213,951
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000213,951415,449409,289497,392
       Short Long Term Debt 
497,392
409,289
415,449
213,951
5,226
7,958
42,568
377,265
388,575
389,379
407,454
421,757
413,444
409,029
400,786
662,767
664,082
461,544
534,848
534,848461,544664,082662,767400,786409,029413,444421,757407,454389,379388,575377,26542,5687,9585,226213,951415,449409,289497,392
       Accounts payable 
103,430
122,056
124,020
117,978
154,028
164,164
132,209
191,497
220,329
268,436
283,662
315,534
354,756
466,382
465,095
406,348
428,664
416,502
400,934
400,934416,502428,664406,348465,095466,382354,756315,534283,662268,436220,329191,497132,209164,164154,028117,978124,020122,056103,430
       Other Current Liabilities 
167,855
433,537
282,008
496,986
571,571
1,059,241
746,075
847,777
1,108,870
1,302,999
1,309,492
1,462,658
1,585,493
1,716,279
1,977,421
22,201
24,554
2,199,854
29,260
29,2602,199,85424,55422,2011,977,4211,716,2791,585,4931,462,6581,309,4921,302,9991,108,870847,777746,0751,059,241571,571496,986282,008433,537167,855
   > Long-term Liabilities 
1,029,233
994,308
1,045,557
827,339
357,260
449,738
630,285
993,264
1,311,170
5,018,913
5,080,237
5,111,821
5,229,673
5,282,421
5,519,341
5,740,257
5,838,197
6,040,507
6,036,402
6,036,4026,040,5075,838,1975,740,2575,519,3415,282,4215,229,6735,111,8215,080,2375,018,9131,311,170993,264630,285449,738357,260827,3391,045,557994,3081,029,233
       Capital Lease Obligations 
0
124,395
111,512
131,160
115,843
157,457
148,740
186,608
171,040
200,804
227,180
284,338
417,986
628,051
627,506
760,515
720,818
672,145
617,049
617,049672,145720,818760,515627,506628,051417,986284,338227,180200,804171,040186,608148,740157,457115,843131,160111,512124,3950
       Long-term Liabilities Other 
880,075
852,445
907,770
673,188
201,843
285,187
0
146,810
147,854
254,808
181,524
81,559
88,928
92,614
101,727
112,093
122,851
111,129
115,863
115,863111,129122,851112,093101,72792,61488,92881,559181,524254,808147,854146,8100285,187201,843673,188907,770852,445880,075
       Deferred Long Term Liability 
235,460
232,848
218,059
204,835
191,879
179,940
167,188
234,271
216,689
198,664
188,077
171,601
206,803
242,268
362,837
0
0
479,422
0
0479,42200362,837242,268206,803171,601188,077198,664216,689234,271167,188179,940191,879204,835218,059232,848235,460
> Total Stockholder Equity
2,822,548
2,833,897
2,994,549
7,767,063
7,857,668
8,133,861
8,464,568
8,870,320
9,097,316
9,366,636
9,757,935
10,129,241
10,204,814
10,155,581
10,401,704
10,548,615
10,979,427
11,535,329
11,904,941
11,904,94111,535,32910,979,42710,548,61510,401,70410,155,58110,204,81410,129,2419,757,9359,366,6369,097,3168,870,3208,464,5688,133,8617,857,6687,767,0632,994,5492,833,8972,822,548
   Common Stock
656,294
656,294
656,294
794,387
794,387
794,387
794,387
794,387
794,387
794,387
794,177
794,177
794,177
1,191,068
1,191,068
0
0
1,786,732
0
01,786,732001,191,0681,191,068794,177794,177794,177794,387794,387794,387794,387794,387794,387794,387656,294656,294656,294
   Retained Earnings 
602,907
622,226
789,283
1,078,245
1,179,763
1,322,022
1,748,130
2,131,489
2,377,363
2,458,139
2,933,366
3,554,394
3,803,481
3,784,633
4,160,308
4,152,381
4,500,709
5,002,552
4,934,072
4,934,0725,002,5524,500,7094,152,3814,160,3083,784,6333,803,4813,554,3942,933,3662,458,1392,377,3632,131,4891,748,1301,322,0221,179,7631,078,245789,283622,226602,907
   Accumulated Other Comprehensive Income 0000000000000000000
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue11,423,751
Cost of Revenue-7,278,525
Gross Profit4,145,2264,145,226
 
Operating Income (+$)
Gross Profit4,145,226
Operating Expense-9,603,195
Operating Income1,820,556-5,457,969
 
Operating Expense (+$)
Research Development401,620
Selling General Administrative1,178,074
Selling And Marketing Expenses-
Operating Expense9,603,1951,579,695
 
Net Interest Income (+$)
Interest Income43,626
Interest Expense-176,829
Other Finance Cost-51,591
Net Interest Income-81,613
 
Pretax Income (+$)
Operating Income1,820,556
Net Interest Income-81,613
Other Non-Operating Income Expenses-
Income Before Tax (EBT)1,779,8651,820,556
EBIT - interestExpense = -176,829
1,552,535
1,729,364
Interest Expense176,829
Earnings Before Interest and Taxes (EBIT)-1,956,694
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax1,779,865
Tax Provision-237,383
Net Income From Continuing Ops1,542,4821,542,482
Net Income1,552,535
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-81,613
 

Technical Analysis of Pharmaron
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharmaron. The general trend of Pharmaron is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharmaron's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharmaron Beijing Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 21.61 < 24.43 < 24.90.

The bearish price targets are: 18.50.

Tweet this
Pharmaron Beijing Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharmaron Beijing Co Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharmaron Beijing Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartPharmaron Beijing Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharmaron Beijing Co Ltd. The current adx is .

Pharmaron Beijing Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Relative Strength Index (RSI) ChartPharmaron Beijing Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Stochastic Oscillator ChartPharmaron Beijing Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Commodity Channel Index (CCI) ChartPharmaron Beijing Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Chande Momentum Oscillator (CMO) ChartPharmaron Beijing Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Williams %R ChartPharmaron Beijing Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Average True Range (ATR) ChartPharmaron Beijing Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily On-Balance Volume (OBV) ChartPharmaron Beijing Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Money Flow Index (MFI) ChartPharmaron Beijing Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharmaron Beijing Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Pharmaron Beijing Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharmaron Beijing Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose20.350
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pharmaron with someone you think should read this too:
  • Are you bullish or bearish on Pharmaron? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharmaron? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharmaron Beijing Co Ltd

I send you an email if I find something interesting about Pharmaron Beijing Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Pharmaron Beijing Co Ltd.

Receive notifications about Pharmaron Beijing Co Ltd in your mailbox!